Researchers at The University of Texas MD Anderson Cancer Center have identified a new way to understand how rapid-acting antidepressants like ketamine and psychedelics function. Although these substances target different brain receptors, they appear to activate the same internal communication signals between the immune system and the brain.
The study focused on specific immune markers, particularly interleukin-15 and interleukin-7, alongside B-cell signaling pathways. Scientists discovered that patients who responded well to ketamine treatment shared a specific pre-treatment immune profile. These individuals typically showed lower levels of the IL-15 pathway and higher baseline B-cell activity before receiving care. Once the treatment took effect, these immune signals normalized, indicating that the drug worked by correcting an imbalance rather than just masking symptoms.
This research bridges the gap between blood-based biomarkers and changes in brain electrical activity. By analyzing these signals, doctors hope to better predict which patients are likely to see positive results from these therapies. This is particularly important for individuals with treatment-resistant depression, including those managing psychological distress alongside a cancer diagnosis.
While traditional antidepressants often require weeks or months to reach full effectiveness, these rapid-acting options provide a different biological path for relief. By mapping the neuroimmune axis, the research team is moving toward a more precise model for prescribing these treatments. This could move psychiatry away from a trial-and-error approach and toward a system where blood tests help select the most effective intervention for each person.
These findings are currently exploratory and require verification through larger clinical trials. Future work will investigate if monitoring these specific markers can help clinicians adjust therapy duration or identify new targets to sustain long-term mental health improvements. By focusing on the interaction between immune signaling and brain waves, scientists are gaining a clearer view of how the body maintains its equilibrium during recovery.